ACTG

Acacia Research Corp. 10-Q Summary (Period Ended Sept 30, 2008)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2008. Acacia Research Corporation operates as an intellectual property firm that acquires, develops, licenses, and enforces patented technologies through wholly owned subsidiaries. As of the reporting date, the company owned or controlled rights to 100 patent portfolios. The company previously split off its CombiMatrix group in August 2007; results for CombiMatrix are presented as discontinued operations.

Key Financial Metrics

Expense Breakdown (Nine Months 2008): Marketing, General & Administrative expenses were $18.4 million (including $5.7 million in non-cash stock compensation). Inventor royalties and contingent legal fees were $17.1 million. Patent-related legal expenses were $3.2 million.

Material Changes vs. Prior Period

• Revenue Decline: Nine-month license fee revenues decreased 26% to $30.0 million from $40.6 million in the prior year period. This was driven by fewer new licensing agreements (60 in 2008 vs. 69 in 2007) and fluctuations in licensee sales.
• Increased Losses: The net loss from continuing operations widened significantly to $12.0 million for the nine months ended Sept 30, 2008, compared to $3.8 million in the same period in 2007. This was primarily due to the revenue decline and increased operating expenses.
• Expense Growth: Marketing, general, and administrative expenses increased by $4.5 million year-over-year for the nine-month period, attributed to personnel additions, higher stock compensation, and increased business development costs.
• Accounts Receivable: Accounts receivable surged to $10.5 million from $1.4 million at year-end 2007, reflecting timing of revenue recognition versus cash collection.

Guidance, Outlook, Risks, and Unusual Items

• Auction Rate Securities (ARS) Risk: The company holds $4.9 million in par value of auction rate securities. Due to failed auctions in the global credit market, $2.75 million of student loan-backed ARS were reclassified as non-current assets. The company recorded an other-than-temporary impairment loss of $250,000 on these assets. Liquidity for these funds is uncertain until auctions succeed or buyers are found.
• Liquidity Outlook: Management believes current cash, investments, and anticipated cash flows are sufficient to meet requirements through at least October 2009. However, the company notes extreme volatility in capital markets and no assurance that additional funding will be available if needed.
• Discontinued Operations: The CombiMatrix split-off resulted in no loss from discontinued operations for the current period, whereas the prior year included a loss of $8.1 million related to the split-off.
• Patent Acquisitions: The company spent $1.8 million acquiring 15 new patent portfolios in the first nine months of 2008, covering technologies such as surgical catheters, vehicle maintenance, and videoconferencing.

Investor Verification Checklist

• ARS Liquidity: Verify the current status of the $2.75 million in student loan-backed auction rate securities and the timeline for potential recovery or further impairment.
• Revenue Concentration: Note that two licensees accounted for 54% of Q3 2008 revenues and one licensee accounted for 20% of YTD 2008 revenues.
• Cash Flow vs. Net Income: Review the disconnect between the $12.0 million net loss and the $4.2 million net cash provided by investing activities (driven by investment sales) versus the $4.2 million cash used in operating activities.
• Contingent Liabilities: Assess the exposure to contingent legal fees and inventor royalties, which totaled $17.1 million for the nine-month period and are directly tied to future revenue recognition.